6-K ·Filed Apr 20, 2026
Notable filing: 6-K
Actionable Insight • Neutral
Monitor for updates on the development timeline and clinical trial progress of the NCEL-101 and tegoprubart combination therapy, as this could be a key catalyst for the stock.
Final — all horizons settled through T+60d ⚠ clustered
NCEL ▲ +38.87% at T+60d
NEUTRAL call +38.87% · α vs SPY +32.09% · entry $2.83 → $3.93
T+1d
+19.43%
call +19.43% · α +20.09%
$3.38
settled 6mo ago
T+5d
+36.75%
call +36.75% · α +35.84%
$3.87
settled 6mo ago
T+20d
+9.89%
call +9.89% · α +5.69%
$3.11
settled 5mo ago
T+60d
+38.87%
call +38.87% · α +32.09%
$3.93
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
NewcelX Ltd. announced a strategic collaboration with Eledon Pharmaceuticals to combine its NCEL-101 stem cell therapy for Type 1 diabetes with Eledon's immune modulation drug tegoprubart. The partnership aims to enhance graft survival and support the development of a potential functional cure for Type 1 diabetes.
Key Facts
- NewcelX is a clinical-stage regenerative medicine company focused on Type 1 diabetes
- The company is advancing its flagship program NCEL-101, a stem cell-derived islet replacement therapy
- NewcelX has entered a strategic collaboration with Eledon Pharmaceuticals
- The collaboration combines NCEL-101 with Eledon's investigational anti-CD40L monoclonal antibody tegoprubart
- Tegoprubart is designed to prevent immune-mediated transplant rejection
- The combination therapy aims to support durable graft survival and advance the development of a potential functional cure for Type 1 diabetes
Financial Impact
Undisclosed amount
revenuedilutiondebt
Risk Factors
- The collaboration is still in early stages and may not lead to a successful treatment
- Clinical trials may encounter delays or fail to meet endpoints
- Regulatory approvals may not be obtained
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-045353 |
| Document: ea0286903-6k_newcelx.htm | 0001213900-26-045353 |
| Document: ea028690301ex99-1.htm | 0001213900-26-045353 |
| Document: 0001213900-26-045353-index-headers.html | 0001213900-26-045353 |
| Document: 0001213900-26-045353-index.html | 0001213900-26-045353 |
| Document: 0001213900-26-045353.txt | 0001213900-26-045353 |
17 reports for NCEL
56% Hit rate @ T+5 Went positive at some point 5 of 9 best @ T+20▲ +95.57%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | EFFECT | $2.86 $3.08 | ▼ −7.52% | ▼ −8.19% | $2.55 (+10.84%) |
Sep 18, 2026 5w ago | 6-K | $2.97 $2.92 | ▲ +1.68% | ▲ +0.66% | $2.55 (+14.14%) |
Aug 27, 2026 8w ago | EFFECT | $3.42 $3.35 | ▲ +2.05% | ▲ +1.28% | $2.55 (+25.44%) |
Jul 31, 2026 12w ago | 6-K | $3.49 $3.31 | ▼ −5.16% | ▼ −8.67% | $2.55 (−26.93%) |
Jul 15, 2026 14w ago | 6-K | $3.93 $3.65 | ▼ −7.12% | ▼ −6.14% | $2.55 (−35.11%) |
Jul 8, 2026 15w ago | 6-K | $4.23 $3.98 | ▼ −5.91% | ▼ −6.77% | $2.55 (−39.72%) |
Jul 1, 2026 16w ago | 6-K | $3.85 $4.01 | ▲ +4.16% | ▲ +3.89% | $2.55 (−33.77%) |
Jun 30, 2026 16w ago | 6-K | $3.85 $4.01 | ▲ +4.16% | ▲ +3.89% | $2.55 (−33.77%) |
Jun 18, 2026 18w ago | EFFECT | $3.31 $3.55 | ▼ −7.25% | ▼ −8.92% | $2.55 (+22.96%) |
Jun 5, 2026 20w ago | 6-K | $3.24 $3.20 | ▼ −1.23% | ▼ −3.35% | $2.55 (−21.30%) |
Showing 10 of 17
US Market Status
Market Closed — Opens in 3h 58m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers